NYSE : RCUS
Arcus Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 18.61 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.68B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.62B |
| Enterprise Value | 2.08B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 143.76M |
| Shares Outstanding | 143.76M |
| Shares Change (YoY) | +22.85% |
| Shares Change (QoQ) | +0.56% |
| Owned by Insiders (%) | 3.19% |
| Owned by Institutions (%) | 64.69% |
| Float | 106.96M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.35 |
| Forward PS | 99.82 |
| PB Ratio | 4.98 |
| P/TBV Ratio | 5.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 17.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.82 |
| Quick Ratio | 3.75 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -44.18 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -90.82% |
| Return on Assets (ROA) | -30.39% |
| Return on Invested Capital (ROIC) | -43.99% |
| Return on Capital Employed (ROCE) | -66.94% |
| Weighted Average Cost of Capital (WACC) | 8.93% |
| Revenue Per Employee | $194,676 |
| Profits Per Employee | -$765,391 |
| Employee Count | 601 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.94 |
| 52-Week Price Change | -10.35% |
| 50-Day Moving Average | 24.98 |
| 200-Day Moving Average | 24.67 |
| Relative Strength Index (RSI) | 30.03 |
| Average Volume (20 Days) | 2,584,880 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.36M |
| Short Previous Month | 13.81M |
| Short % of Shares Out | 8.60% |
| Short % of Float | 11.55% |
| Short Ratio (days to cover) | 8.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 117.00M |
| Gross Profit | -380.00M |
| Operating Income | -486.00M |
| Pretax Income | -460.00M |
| Net Income | -460.00M |
| EBITDA | -476.00M |
| EBIT | -486.00M |
| Loss Per Share | -$3.86 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 702.00M |
| Total Debt | 238.00M |
| Net Cash | 537.00M |
| Net Cash Per Share | $3.74 |
| Equity (Book Value) | 464.00M |
| Book Value Per Share | 3.65 |
| Working Capital | 558.00M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -474.00M |
| Capital Expenditures | -1.00M |
| Depreciation & Amortization | 10.00M |
| Net Borrowing | n/a |
| Free Cash Flow | -475.00M |
| FCF Per Share | -$3.30 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -415.38% |
| Pretax Margin | -393.16% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.85% |
| Shareholder Yield | -22.85% |
| Earnings Yield | -21.24% |
| FCF Yield | -18.16% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $41.00 |
| Price Target Difference | 125.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | -15.14% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.44 |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |